SLC5A2 and hydrops fetalis: At the time of HECMOS 1 (May 2022), SGLT2 inhibitors were already included in European Society of Cardiology (ESC) guidelines [9] as a foundational therapy for patients with HF and a reduced ejection fraction (HFrEF).